Skip survey header

BLADDR2019 - case 3

Thank You!

Your case challenge on the optimal bladder preservation therapy

View case
You answered: A
You answered: A
A) Radiation therapy alone - B) Radiation therapy + carbogen and nicotinamide (BCON) - C) Chemoradiation therapy
 

What would Ananya Choudhury do? 

This patient has organ-confined muscle-invasive bladder cancer; he has no positive lymph nodes or metastases. He has no hydronephrosis, but his renal function is impaired. He underwent a complete TURBT.

This patient can be treated with chemoradiation or BCON, so option B and C are both correct. There is no evidence of superiority of one over the other. At ESTRO 2019, long-term outcomes of the BCON trial were presented. These confirmed that BCON has an overall survival benefit and is very well tolerated with minimal toxicity. In low and middle income countries, BCON is easily deliverable and has economic advantages.

Come and join us in Paris for BLADDR19 on 25-26th October to see the updated data and discuss the data further.
 
 


What would Ananya Choudhury do?

This patient has organ-confined muscle-invasive bladder cancer; he has no positive lymph nodes or metastases. He has no hydronephrosis, but his renal function is impaired. He underwent a complete TURBT.

This patient can be treated with chemoradiation or BCON, so option B and C are both correct. There is no evidence of superiority of one over the other. At ESTRO 2019, long-term outcomes of the BCON trial were presented. These confirmed that BCON has an overall survival benefit and is very well tolerated with minimal toxicity. In low and middle income countries, BCON is easily deliverable and has economic advantages.


Come and join us in Paris for BLADDR19 on 25-26th October to see the updated data and discuss the data further.
 

Do you have an interesting case of your own?

Up to 3 case reports will be selected by the scientific committee for discussion in the official programme of BLADDR 2019.
 

Submit your case
 


Join us at BLADDR 2019 to get a full update on bladder cancer and discuss with faculty and peers how 2019 highlights will impact your daily practice.


Reserve your seat